Market capitalization | $8.15b |
Enterprise Value | $8.33b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 23.51 |
P/S ratio (TTM) P/S ratio | 22.99 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 117.15% |
Revenue (TTM) Revenue | $354.45m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
14 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:
14 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | 354 354 |
117%
117%
|
|
Gross Profit | 285 285 |
146%
146%
|
|
EBITDA | -323 -323 |
45%
45%
|
EBIT (Operating Income) EBIT | -342 -342 |
43%
43%
|
Net Profit | -462 -462 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
Head office | Denmark |
CEO | Jan Mikkelsen |
Founded | 2006 |
Website | www.ascendispharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.